Clinical applications of hematopoietic growth factors. 1993

L Williams
Medical Technology Program, School of Health Sciences, Oakland University, Rochester, Michigan 48063.

OBJECTIVE To explore the history and current clinical uses of hematopoietic growth factors. METHODS Recent professional literature and texts dealing with recombinant DNA technology, the development of hematopoietic growth factors, and their use in various disease states. METHODS Not specified. METHODS Not specified. RESULTS Hematopoietic growth factors are glycoproteins that regulate the differentiation and proliferation of hematopoietic precursor cells, and, in some cases, the function of mature blood cells. Several have been molecularly characterized and produced in quantity via recombinant DNA technology. Medically, hematopoietic growth factors can be used to replenish hematopoietic lineages by raising cell counts to normal levels; to augment host defenses against infection; to stimulate the immune system against malignancy; and to increase production of effector cells with cytotoxic activities. CONCLUSIONS In the past eight years, the hematopoietic growth factors have been used in a variety of clinical settings. They have proven to be effective in stimulating marrow proliferation, increasing circulating blood cell counts, and stimulating various host defense mechanisms. Others are in earlier stages of clinical studies, and their full therapeutic potential remains to be evaluated. New therapies are expected to emerge at a rapid pace.

UI MeSH Term Description Entries
D007378 Interleukins Soluble factors which stimulate growth-related activities of leukocytes as well as other cell types. They enhance cell proliferation and differentiation, DNA synthesis, secretion of other biologically active molecules and responses to immune and inflammatory stimuli. Interleukin
D011956 Receptors, Cell Surface Cell surface proteins that bind signalling molecules external to the cell with high affinity and convert this extracellular event into one or more intracellular signals that alter the behavior of the target cell (From Alberts, Molecular Biology of the Cell, 2nd ed, pp693-5). Cell surface receptors, unlike enzymes, do not chemically alter their ligands. Cell Surface Receptor,Cell Surface Receptors,Hormone Receptors, Cell Surface,Receptors, Endogenous Substances,Cell Surface Hormone Receptors,Endogenous Substances Receptors,Receptor, Cell Surface,Surface Receptor, Cell
D006402 Hematologic Diseases Disorders of the blood and blood forming tissues. Blood Diseases,Hematological Diseases,Blood Disease,Disease, Blood,Disease, Hematologic,Disease, Hematological,Diseases, Blood,Diseases, Hematologic,Diseases, Hematological,Hematologic Disease,Hematological Disease
D006412 Hematopoietic Stem Cells Progenitor cells from which all blood cells derived. They are found primarily in the bone marrow and also in small numbers in the peripheral blood. Colony-Forming Units, Hematopoietic,Progenitor Cells, Hematopoietic,Stem Cells, Hematopoietic,Hematopoietic Progenitor Cells,Cell, Hematopoietic Progenitor,Cell, Hematopoietic Stem,Cells, Hematopoietic Progenitor,Cells, Hematopoietic Stem,Colony Forming Units, Hematopoietic,Colony-Forming Unit, Hematopoietic,Hematopoietic Colony-Forming Unit,Hematopoietic Colony-Forming Units,Hematopoietic Progenitor Cell,Hematopoietic Stem Cell,Progenitor Cell, Hematopoietic,Stem Cell, Hematopoietic,Unit, Hematopoietic Colony-Forming,Units, Hematopoietic Colony-Forming
D006801 Humans Members of the species Homo sapiens. Homo sapiens,Man (Taxonomy),Human,Man, Modern,Modern Man
D016298 Hematopoietic Cell Growth Factors These growth factors comprise a family of hematopoietic regulators with biological specificities defined by their ability to support proliferation and differentiation of blood cells of different lineages. ERYTHROPOIETIN and the COLONY-STIMULATING FACTORS belong to this family. Some of these factors have been studied and used in the treatment of chemotherapy-induced neutropenia, myelodysplastic syndromes, and bone marrow failure syndromes. Hematopoietins,Hematopoietic Cell Growth Factor,Hematopoietic Stem Cell Stimulators,Hematopoietic Stem Cell-Activating Factors,Hematopoietic-CGF,Hematopoietic CGF
D016896 Treatment Outcome Evaluation undertaken to assess the results or consequences of management and procedures used in combating disease in order to determine the efficacy, effectiveness, safety, and practicability of these interventions in individual cases or series. Rehabilitation Outcome,Treatment Effectiveness,Clinical Effectiveness,Clinical Efficacy,Patient-Relevant Outcome,Treatment Efficacy,Effectiveness, Clinical,Effectiveness, Treatment,Efficacy, Clinical,Efficacy, Treatment,Outcome, Patient-Relevant,Outcome, Rehabilitation,Outcome, Treatment,Outcomes, Patient-Relevant,Patient Relevant Outcome,Patient-Relevant Outcomes

Related Publications

L Williams
September 1988, Lakartidningen,
L Williams
April 1995, Journal of clinical oncology : official journal of the American Society of Clinical Oncology,
L Williams
July 1994, Current opinion in hematology,
L Williams
November 1989, The New England journal of medicine,
L Williams
June 1992, Casopis lekaru ceskych,
L Williams
May 2002, Current opinion in hematology,
L Williams
September 1990, The American journal of the medical sciences,
L Williams
November 1990, The American journal of the medical sciences,
L Williams
October 1990, The American journal of the medical sciences,
L Williams
May 2010, Annals of oncology : official journal of the European Society for Medical Oncology,
Copied contents to your clipboard!